Amphastar Pharmaceuticals, Inc. (AMPH): Free Cash Flow
$121.23M
Year ended 2025-12-31
$152.89M
Trailing 12 months to 2026-06-30
+23.0%
3-year compound annual growth
+38.9%
5-year compound annual growth
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $121.23M | -29.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $172.34M | +18.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $145.34M | +123.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $65.15M | -7.6% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $70.54M | +201.3% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $23.41M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $207.0K | n/m | 2022-03-11, From 2019-01-01 |
| 2018-12-31 | -$8.62M | n/m | 2021-03-15, From 2018-01-01 |
| 2017-12-31 | $4.11M | -76.1% | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | $17.18M | n/m | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | -$5.32M | n/m | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $553.0K | n/c | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | $13.40M | n/m | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | -$24.78M | n/a | 2015-03-26, From 2012-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $121.23M | -29.7% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $45.99M | -73.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $136.66M | -23.5% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $156.80M | +338.0% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $141.78M | -27.7% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $136.42M | +436.8% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$472.00M | n/m |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $327.58M | +61.1% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$93.89M | n/m |
Compare AMPH, SUPN, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗